Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Jakopovic

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory Cell and Molecular Biology|October 30, 2004
The consequences of insulin-like growth factors/receptors dysfunction in lung cancerJasminka Pavelic, Simun Krizanac, Sanja Kapitanovic, et al.
Radiology and Oncology|October 13, 2020
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern EuropeMilada Zemanova, Marko Jakopovic, Karmen Stanic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Characterization and management of cardiac involvement of thymic epithelial tumorsAnish Thomas, Sujata Shanbhag, Karl Haglund, et al.
The Oncologist|March 13, 2020
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group AnalysisTanja Cufer, Tudor E Ciuleanu, Peter Berzinec, et al.
BMC Proceedings|January 17, 2024
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityMaximilian J Hochmair, Mojca Unk, Jelena Spasic, et al.
Radiology and Oncology|September 4, 2023
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysisLidija Ljubicic, Urska Janzic, Mojca Unk, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, et al.
Diagnostics (Basel, Switzerland)|May 4, 2026
MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural MesotheliomaBerta Mosleh, Yawen Dong, Elisabeth Lang, et al.
Annals of Translational Medicine|June 9, 2016
A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?Katherina-Bernadette Sreter, Marko Jakopovic, Zoran Janevski, et al.
Thoracic Cancer|June 21, 2023
Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosisBerta Mosleh, Karin Schelch, Thomas Mohr, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory Cell and Molecular Biology|October 30, 2004
The consequences of insulin-like growth factors/receptors dysfunction in lung cancerJasminka Pavelic, Simun Krizanac, Sanja Kapitanovic, et al.
Radiology and Oncology|October 13, 2020
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern EuropeMilada Zemanova, Marko Jakopovic, Karmen Stanic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Characterization and management of cardiac involvement of thymic epithelial tumorsAnish Thomas, Sujata Shanbhag, Karl Haglund, et al.
The Oncologist|March 13, 2020
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group AnalysisTanja Cufer, Tudor E Ciuleanu, Peter Berzinec, et al.
BMC Proceedings|January 17, 2024
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availabilityMaximilian J Hochmair, Mojca Unk, Jelena Spasic, et al.
Radiology and Oncology|September 4, 2023
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysisLidija Ljubicic, Urska Janzic, Mojca Unk, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, et al.
Diagnostics (Basel, Switzerland)|May 4, 2026
MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural MesotheliomaBerta Mosleh, Yawen Dong, Elisabeth Lang, et al.
Annals of Translational Medicine|June 9, 2016
A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?Katherina-Bernadette Sreter, Marko Jakopovic, Zoran Janevski, et al.
Thoracic Cancer|June 21, 2023
Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosisBerta Mosleh, Karin Schelch, Thomas Mohr, et al.
Pageof 4